CCNC (Ab-275) Antibody

What is CCNC (Ab-275) Antibody and what specific epitope does it recognize?

CCNC (Ab-275) Antibody is a rabbit polyclonal antibody that specifically recognizes human Cyclin C protein around the phosphorylation site of serine 275. The immunogen used to produce this antibody is a synthesized non-phosphopeptide derived from human Cyclin C with the sequence N-G-S(p)-Q-N . This antibody detects endogenous levels of total Cyclin C protein regardless of phosphorylation status at Ser275 .

Cyclin C serves as a component of the Mediator complex, which functions as a coactivator involved in regulated gene transcription of nearly all RNA polymerase II-dependent genes. Specifically, it binds to and activates cyclin-dependent kinase CDK8, which phosphorylates the C-terminal domain (CTD) of the large subunit of RNA polymerase II, potentially inhibiting the formation of a transcription initiation complex .

What validated applications does CCNC (Ab-275) Antibody support in research settings?

Based on validation studies, CCNC (Ab-275) Antibody has been confirmed for the following applications:

The antibody has demonstrated successful detection of endogenous levels of Cyclin C in various experimental contexts, particularly in human and mouse samples . Researchers should note that while these applications are validated, optimization for specific experimental conditions may be necessary.

What is the recommended storage protocol to maintain antibody integrity?

To maintain optimal antibody performance, CCNC (Ab-275) Antibody should be stored at -20°C or -80°C upon receipt . Avoid repeated freeze-thaw cycles as these can compromise antibody activity through protein denaturation and aggregation. The antibody is supplied in rabbit IgG in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol , which helps maintain stability during freezing.

For routine use, aliquoting the antibody into single-use volumes before freezing is recommended to minimize freeze-thaw cycles. When removing from freezer storage, thaw on ice and centrifuge briefly before use to collect all liquid at the bottom of the tube.

How should CCNC (Ab-275) Antibody be validated for specificity in different experimental systems?

When using CCNC (Ab-275) Antibody in a new experimental system, validation is critical to ensure specificity. Implement the following multi-step validation strategy:

• Positive and negative controls: Include known Cyclin C-expressing and non-expressing samples in parallel experiments.

• Knockdown/knockout validation: Compare antibody staining in wild-type versus CCNC knockdown (siRNA) or knockout samples. This approach provides the most definitive evidence of specificity.

• Peptide competition assay: Pre-incubate the antibody with excess immunizing peptide (N-G-S(p)-Q-N) before application to samples. Signal disappearance confirms specificity for the target epitope.

• Molecular weight verification: In Western blot applications, confirm that the detected band corresponds to the expected molecular weight of Cyclin C (~33 kDa) .

• Cross-validation with alternative antibodies: Compare results with other validated anti-Cyclin C antibodies targeting different epitopes.

This comprehensive validation approach is particularly important given documented cases of cross-reactivity with antibodies against other nuclear proteins, as seen with an antibody against NCAPH2 that showed cross-reactivity with SWI/SNF complex components .

What controls should be included when using CCNC (Ab-275) Antibody in Western blot experiments?

A robust Western blot experiment using CCNC (Ab-275) Antibody should include these essential controls:

• Positive control: Cell lysate known to express Cyclin C (e.g., LOVO cells have been documented to express detectable levels of Cyclin C) .

• Loading control: Probing for housekeeping proteins (e.g., GAPDH, β-actin) to ensure equal loading across samples.

• Negative control: Either:

  • Primary antibody omission control

  • Sample with Cyclin C knocked down/knocked out

  • Non-specific rabbit IgG at the same concentration as the primary antibody

• Molecular weight marker: To confirm the detected band appears at the expected size of ~33 kDa for Cyclin C .

• Antibody titration: Testing different dilutions (within the recommended 1:500-1:3000 range) to determine optimal signal-to-noise ratio for your specific samples .

Including these controls allows for rigorous interpretation of results and troubleshooting of potential experimental issues.

How can potential cross-reactivity of CCNC (Ab-275) Antibody be assessed and mitigated?

Antibody cross-reactivity is a significant concern in research applications. For CCNC (Ab-275) Antibody, employ these strategies to assess and mitigate potential cross-reactivity:

• IP-Mass Spectrometry analysis: Perform immunoprecipitation followed by mass spectrometry to identify all proteins pulled down by the antibody, similar to the approach used in study . This provides an unbiased assessment of all potential cross-reactive targets.

• Parallel knockout validations: Test antibody reactivity in wild-type versus CCNC knockout samples. Persistent signal in knockout samples indicates cross-reactivity.

• Epitope alignment analysis: Perform in silico analysis to identify proteins with sequence similarity to the immunizing peptide (N-G-S(p)-Q-N).

• Pre-adsorption controls: Pre-incubate the antibody with the immunizing peptide before use to block specific binding.

• Multi-antibody validation: Compare results with other anti-Cyclin C antibodies targeting different epitopes.

This is particularly important in light of findings from study , which demonstrated that a commercial antibody against NCAPH2 cross-reacted with SWI/SNF complex components in an NCAPH2-independent manner, potentially confounding interpretation of results.

How can CCNC (Ab-275) Antibody be incorporated into multiplexed immunoassays?

Incorporating CCNC (Ab-275) Antibody into multiplexed immunoassays requires careful consideration of potential cross-reactivity between detection antibodies. Based on approaches described in , researchers can implement these strategies:

• Physical separation using aqueous two-phase systems (ATPS): This method confines detection antibody solutions to regions with complementary capture antibodies, preventing cross-reactions between different detection antibodies .

• Spectral unmixing: When using fluorescently labeled antibodies, select fluorophores with minimal spectral overlap and apply computational unmixing algorithms.

• Sequential antibody application: Apply and detect antibodies sequentially with washing and blocking steps between applications.

• Cross-reactivity pre-screening: Before multiplexing, test all antibodies in the panel for cross-reactivity against all capture antibodies.

• Species-specific secondary antibodies: When possible, use primary antibodies from different host species to enable discrimination through species-specific secondary antibodies.

When implementing these approaches, validation should include comparison of multiplexed results with single-antibody controls to confirm signal specificity and quantitative accuracy .

What are the considerations for using CCNC (Ab-275) Antibody to study Cyclin C in the context of the Mediator complex?

Studying Cyclin C within the Mediator complex using CCNC (Ab-275) Antibody requires special considerations due to the complex's size and protein-protein interactions:

• Epitope accessibility: The antibody targets residues around Ser275, which may have differential accessibility when Cyclin C is incorporated into the Mediator complex. Gentle fixation and optimization of protein extraction methods are crucial.

• Co-immunoprecipitation optimization: When using this antibody for Co-IP of Mediator complex components:

  • Use gentle lysis conditions to preserve protein-protein interactions

  • Consider crosslinking approaches to stabilize transient interactions

  • Include appropriate detergent concentrations to maintain complex integrity while enabling antibody access

• Comparative analysis with CDK8 module components: Include parallel analysis of other CDK8 module components (CDK8, MED12, MED13) to verify detection of the intact module.

• Chromatin association studies: When studying chromatin-associated Mediator complex, optimize extraction conditions to distinguish between soluble and chromatin-bound fractions.

• Functional validation: Complement immunodetection with functional assays of Mediator activity to correlate detection with biological function.

This antibody can provide insights into Cyclin C's role in the Mediator complex as a coactivator involved in regulated gene transcription of RNA polymerase II-dependent genes .

How does phosphorylation status at Ser275 potentially affect binding of CCNC (Ab-275) Antibody?

The CCNC (Ab-275) Antibody was raised against a non-phosphopeptide derived from human Cyclin C around the phosphorylation site of serine 275 . This has important implications for detection and experimental design:

• Total vs. phospho-specific detection: This antibody detects total Cyclin C regardless of Ser275 phosphorylation status. For phosphorylation-specific detection, researchers should consider using phospho-specific antibodies like Anti-Cyclin C (phospho Ser275) Antibody .

• Epitope masking considerations: Post-translational modifications including phosphorylation can potentially affect antibody binding through:

  • Conformational changes in the protein structure

  • Direct steric hindrance at the binding site

  • Altered protein-protein interactions that may mask the epitope

• Comparative analysis approach: For comprehensive analysis of Ser275 phosphorylation role:

  • Use both CCNC (Ab-275) Antibody and phospho-specific antibodies in parallel

  • Compare relative signal intensities under different conditions

  • Include phosphatase treatment controls to verify phosphorylation-dependent effects

• Functional significance: When studying Cyclin C phosphorylation, consider that phosphorylation at Ser275 may regulate:

  • CDK8 activation

  • Mediator complex assembly or activity

  • RNA polymerase II transcription initiation

This understanding enables more precise experimental design and interpretation when studying Cyclin C regulation through post-translational modifications.

What are common technical issues encountered with CCNC (Ab-275) Antibody in Western blotting and how can they be resolved?

When using CCNC (Ab-275) Antibody in Western blotting, researchers may encounter several technical challenges. Here are common issues and their solutions:

For optimal results with CCNC (Ab-275) Antibody, use LOVO cell lysates as a positive control as documented in prior validation , and maintain consistent experimental conditions once optimized.

How can researchers distinguish between specific binding and artifacts when using CCNC (Ab-275) Antibody in immunofluorescence?

Although CCNC (Ab-275) Antibody is not explicitly validated for immunofluorescence in the provided data, researchers may still attempt this application with proper controls. To distinguish between specific binding and artifacts:

• Include comprehensive controls:

  • Peptide competition: Pre-incubate antibody with immunizing peptide

  • Secondary-only control: Omit primary antibody

  • Isotype control: Use non-specific rabbit IgG

  • Knockdown/knockout control: Compare signal in CCNC-depleted samples

• Co-localization analysis:

  • Perform co-staining with antibodies against known Cyclin C interactors (e.g., CDK8)

  • Expected nuclear localization pattern for Cyclin C

  • Visualization with confocal microscopy to assess subcellular localization

• Signal validation techniques:

  • Compare staining pattern with multiple antibodies against different Cyclin C epitopes

  • Correlate staining intensity with known expression levels in different cell types

  • Consider photobleaching controls to distinguish true signal from autofluorescence

• Nuclear marker co-staining:

  • Include DAPI or other nuclear counterstain

  • Confirm expected nuclear localization of Cyclin C

  • Examine signal distribution relative to subnuclear structures

These approaches help establish confidence in the specificity of immunofluorescence signals, particularly important given potential cross-reactivity concerns noted with some nuclear protein antibodies .

What strategies can overcome epitope masking issues when using CCNC (Ab-275) Antibody?

Epitope masking can occur due to protein-protein interactions, conformational changes, or post-translational modifications affecting the region around Ser275 in Cyclin C. To overcome these challenges:

• Optimized sample preparation:

  • Test multiple lysis buffers with varying detergent concentrations

  • Compare different fixation methods if applicable (e.g., PFA vs. methanol)

  • Evaluate the effect of denaturing vs. non-denaturing conditions

• Epitope retrieval techniques:

  • Heat-induced epitope retrieval (HIER) using citrate or EDTA buffers

  • Enzymatic epitope retrieval using proteinase K or trypsin

  • Evaluation of pH conditions (pH 6.0 vs. pH 9.0) for optimal retrieval

• Protein modification approaches:

  • Phosphatase treatment to remove phosphorylation that might mask epitopes

  • Deglycosylation enzymes if glycosylation affects accessibility

  • Protein crosslinking reversal if applicable

• Alternative detection strategies:

  • Indirect detection methods with signal amplification

  • Use of alternative antibodies targeting different Cyclin C epitopes in parallel

  • Consideration of proximity ligation assays for detection of protein complexes

Implementing these strategies can significantly improve detection of Cyclin C in complex samples where the epitope may be partially occluded due to biological context.

How can CCNC (Ab-275) Antibody be utilized in studying the role of Cyclin C in cancer and therapeutic development?

Cyclin C plays critical roles in transcriptional regulation through the Mediator complex, with potential implications in cancer biology. CCNC (Ab-275) Antibody can be applied in cancer research through these approaches:

• Expression profiling across cancer types:

  • Quantitative Western blot analysis of Cyclin C levels across cancer cell lines

  • Correlation of expression with cancer subtype, stage, and patient outcomes

  • Comparative analysis with other CDK8 module components

• Functional studies in cancer models:

  • Analysis of Cyclin C expression before and after treatment with CDK inhibitors

  • Correlation of expression with therapeutic response

  • Evaluation as a potential biomarker for treatment selection

• Integration with multiplexed approaches:

  • Incorporation into multiplexed antibody panels using technologies like those described in

  • Correlation with expression of other cancer-related proteins

  • Development of predictive expression signatures

• Therapeutic antibody development:

  • Using structural insights from antibody-antigen interactions as described in

  • Evaluation of epitope accessibility in different cellular contexts

  • Development of antibody derivatives based on structure-function relationships

This antibody can contribute to understanding Cyclin C's role in cancer progression and potentially inform therapeutic strategies targeting the CDK8-Cyclin C complex .

What approaches can integrate CCNC (Ab-275) Antibody with emerging single-cell technologies?

Integrating CCNC (Ab-275) Antibody with single-cell technologies offers opportunities to explore Cyclin C expression and function at unprecedented resolution:

• Antibody conjugation for single-cell proteomics:

  • Direct conjugation with fluorophores, metals, or barcodes for CyTOF, CODEX, or other single-cell proteomics platforms

  • Optimization of conjugation chemistry to maintain epitope binding

  • Validation of conjugated antibodies against unconjugated controls

• Integration with spatial proteomics:

  • Incorporation into multiplexed immunofluorescence panels

  • Cyclic immunofluorescence (CyCIF) to build high-parameter tissue maps

  • Correlation of Cyclin C expression with spatial tissue organization

• Deep repertoire mining approaches:

  • Application in technologies similar to those described in for detecting rare cell populations

  • Analysis of Cyclin C expression heterogeneity within seemingly homogeneous populations

  • Correlation with single-cell transcriptomics data

• Microdevice-based applications:

  • Incorporation into multiplex implantable microdevice assays as described in

  • In situ analysis of drug responses related to Cyclin C expression

  • Real-time monitoring of expression changes in response to perturbations

These approaches enable examination of cellular heterogeneity in Cyclin C expression and function, potentially revealing subpopulations with distinct roles in normal physiology and disease .

How might computational methods enhance the utility of CCNC (Ab-275) Antibody in research?

Advanced computational approaches can significantly extend the utility of data generated using CCNC (Ab-275) Antibody:

• Structural prediction and epitope analysis:

  • In silico analysis of antibody-antigen interactions

  • Prediction of conformational changes that might affect epitope accessibility

  • Molecular dynamics simulations to understand binding kinetics

• Image analysis automation:

  • Machine learning algorithms for quantitative analysis of immunofluorescence data

  • Automated detection of subcellular localization patterns

  • Integration of multiple markers for complex phenotype identification

• Multi-omics data integration:

  • Correlation of protein expression data with transcriptomics and epigenomics

  • Network analysis to identify Cyclin C-associated pathways

  • Causal inference models to distinguish drivers from passengers in expression networks

• Synthetic antibody-antigen binding simulations:

  • Approaches similar to those described in for predicting binding affinity

  • Optimization of experimental conditions based on computational predictions

  • Generation of synthetic training data for machine learning applications

These computational approaches can enhance experimental design, data interpretation, and hypothesis generation when working with CCNC (Ab-275) Antibody, particularly in complex systems where multiple variables affect protein expression and function .

How does CCNC (Ab-275) Antibody compare with phospho-specific antibodies in studying Cyclin C function?

When investigating Cyclin C function, researchers must consider the complementary information provided by total protein detection versus phosphorylation-specific detection:

For comprehensive analysis, using both antibody types in parallel provides complementary data - total protein levels from CCNC (Ab-275) Antibody and specific phosphorylation status from phospho-specific antibodies . This approach enables calculation of the phosphorylated fraction of total Cyclin C, offering insights into both expression and post-translational regulation.

What are the considerations when choosing between different commercially available antibodies targeting Cyclin C?

When selecting among different commercial antibodies targeting Cyclin C, researchers should evaluate these key parameters:

• Epitope differences and their implications:

  • CCNC (Ab-275) Antibody: Targets region around Ser275

  • Other antibodies: May target different epitopes, affecting detection in various contexts

  • Consider epitope accessibility in your experimental system

• Validation depth comparison:

  • Review available validation data (Western blot images, knockout controls)

  • Check for peer-reviewed publications using specific antibodies

  • Evaluate species cross-reactivity relevant to your model system

• Application-specific performance:

  • Some antibodies may perform better in specific applications (WB vs. IF vs. IP)

  • Compare recommended dilutions and reported signal-to-noise ratios

  • Consider whether native or denatured protein detection is required

• Specific experimental requirements:

  • For phosphorylation studies: Consider phospho-specific antibodies

  • For co-IP: Evaluate antibodies validated for immunoprecipitation

  • For tissue studies: Check antibodies validated for IHC/IF

• Host species considerations:

  • Compatibility with other antibodies in multiplexed applications

  • Available secondary antibody options

  • Potential background in tissues from the same species

This comparative analysis enables selection of the optimal Cyclin C antibody for specific experimental questions and systems .